

Original

Influence of an immuno-enhanced formula in postsurgical ambulatory patients with head and neck cancer

O. Izaola, D. A de Luis, L. Cuellar, MC Terroba, M Ventosa, T Martin, R Aller

Institute of Endocrinology and Nutrition, Medicine School and Unit of Investigation Hospital Rio Hortega. University of Valladolid. Valladolid Spain.

Abstract

Background: Patients with head and neck cancer undergoing surgery have a high incidence of ambulatory postoperative complications.

Objective: The aim of our study was to investigate the influence of an oral immunoenhanced supplement (arginine and glutamine) on nutritional and biochemical parameters in postsurgical ambulatory patients with head and neck tumor.

Design: A population of 39 ambulatory postsurgical patients with oral and laryngeal cancer was enrolled. At Hospital discharge postsurgical head and neck cancer patients were asked to consume two units per day of a specially designed enhanced supplement for a twelve week period.

Results: The mean age was 60.2±13.1 years (9 female/30 males). Duration of supplementation was 90.8±20 days. A significant increase of albumin (3.1±0.6 g/dl vs 4.12±0.7g /dl;p<0.05), prealbumin (21.4±6.3 mg/dl vs 22.4±5.9 mg/dl;p<0.05) and transferrin (198.8±45.2 mg/dl vs 253.8±60.7 mg/dl; p<0.05) levels were observed. No differences were detected in weight and other anthropometric parameters. Ten patients (41.3%) received radiotherapy along the enhanced supplementation period and only 5 (20% of patients with radiotherapy) developed a clinical oral mucositis.

Conclusions: At dose used, arginine and glutamine enhanced formula improved seric protein levels in ambulatory postoperative head and neck cancer patients with a low rate of oral mucositis in the subgroup with radiotherapy.

(*Nutr Hosp.* 2010;25:793-796)

DOI:10.3305/nh.2010.25.5.4529

Key words: Ambulatory. Arginine. Glutamin. Head and neck cancer. Immunonutrition.

Correspondence: Dr. D. A de Luis.
Professor Associated of Clinical Nutrition.
Head of Institute of Endocrinology and Nutrition.
Medicine School. Valladolid University.
C/Los perales 16. (Urb Las Aceñas).
Simancas 47130 Valladolid.
E-mail: dadluis@yahoo.es

Recibido: 25-IX-2009.
Aceptado: 26-X-2009.

INFLUENCIA DE UNA FORMULA INMUNOENRIQUECIDA EN PACIENTES AMBULATORIOS POSTQUIRURGICOS CON CANCER DE CABEZA Y CUELLO.

Resumen

Antecedentes: Los pacientes con tumores de cabeza y cuello sometidos a cirugía presentan una alta incidencia de complicaciones ambulatorias.

Objetivo: El principal objetivo de nuestro trabajo fue evaluar la influencia de un suplemento oral inmunoenriquecido con arginina y glutamina en pacientes postquirúrgicos ambulatorios con tumores de cabeza y cuello.

Diseño: Una muestra de 39 pacientes postquirúrgicos ambulatorios con tumores de cabeza y cuello fue evaluada. Tras el alta hospitalaria, los pacientes recibieron dos bricks al día de un suplemento inmunoenriquecido durante 12 semanas.

Resultados: La edad media fue de 60,2±13,1 años (9 mujeres/30 varones). La duración media de la suplementación fue de 90,8±20 días. Se detectó un aumento significativo en los niveles de albúmina (3,1±0,6 g/dl vs 4,12±0,7 mg/dl;p<0,05), prealbúmina (21,4±6,3 mg/dl vs 22,4±5,9 mg/dl;p<0,05) y transferrina (198,8±45,2 mg/dl vs 253,8±60,7 mg/dl; p<0,05). No se detectaron diferencias en el peso ni en otras variables antropométricas. Un total de 10 pacientes (41,3%) recibieron radioterapia durante la suplementación, de los cuales solo 2 (20% de los pacientes con radioterapia) desarrollaron mucositis oral con significación clínica.

Conclusiones: A la dosis usada, la formula enriquecida con arginina y glutamina mejoró lo niveles de proteínas séricas. Por otra parte los pacientes suplementados presentaron una baja tasa de mucositis asociada a la radioterapia.

(*Nutr Hosp.* 2010;25:793-796)

DOI:10.3305/nh.2010.25.5.4529

Palabras clave: Ambulatorio. Arginina. Glutamina. Cáncer de cabeza y cuello. Immunonutrición.

Introduction

Patients with head and neck cancer undergoing surgery have a high incidence of malnutrition¹ and it is known that immune system is frequently affected in these patients². Although immune dysfunction could be multifactorial, this immune system may be modulated by specific nutritional substrates, such as omega 3 fatty acids³. Administration of n-3 fatty acid or high purity EPA capsules has been associated with weight stabilization in patients with pancreatic cancer⁴. Good tolerance and an improvement on serum proteins have been demonstrated in patients with head and neck cancer⁵. Arginine is other immunonutrient that could play an important role in this type of patients. It has demonstrated in head and neck cancer patients with enteral arginine enhanced after surgery an improvement in weight and complications rate⁶. For patients with head-and-neck cancer receiving radiotherapy, glutamine has been demonstrated as an effective preventive measure to decrease the severity of mucositis⁷.

The aim of our study was to investigate the influence of an oral immunoenhanced supplement (arginine and glutamine) in nutritional and biochemical parameters in postsurgical ambulatory patients with head and neck tumor.

Material and methods

Patients

A population of 39 ambulatory postsurgical patients with oral and laryngeal cancer was enrolled. Exclusion criteria included; severely impaired hepatic function (total bilirubin concentration >3.5 mg/dl) and renal function (serum creatinine concentration >2.5 mg/dl), ongoing infections, major gastrointestinal disease, autoimmune disorders, steroids treatment, and medication could modulate metabolism or weight. The study was prospective and carried out from May 2007 to May 2009. Baseline studies on all patients at the moment of Hospital discharge after surgery consisted of complete history taking and physical examination. General assessment of nutritional status included measurements of height, body weight, body mass index (kg/m²), circumferences and tricipital skinfold of the midarm with an additional bio impedance.

Nutrition

At Hospital discharge postsurgical head and neck cancer patients were asked to consume two units per day of a specially designed immunoenhanced supplement (enriched with arginine and glutamine: Impact oral (r) plus Resource glutamina (r) for a twelve week period. Table I shows the composition of the supplement. Three day diet diaries completed at baseline (week 0), and weeks 12 were used to assess the patient's dietary intakes. One weekend day and two

Table I
Composition of supplement

	<i>Composition (1 unit 237 ml)</i>
Total energy(Kcal)	334
Protein (g)	18.1
Free L-arginine	4.2
Casein	13.9
Total lipid (g)	9.2
W6	1.45
W3	1.59
MCT	2.7
Carbohydrate (g)	44.7
Dietary fiber (g)	3.3
Glutamine (g)	5

Dietary fiber: guar gum from Impact oral (r). Glutamine was added as a powder formula to the original immunoenhanced formula from Resource glutamine (r).

weekdays were studied to account for potential day of the week effects on dietary intake. A dietitian instructed patients on how to record food and beverage intake. Mean total energy and macronutrient intakes were calculated using country specific computerized dietary analysis packages. Total dietary intake was calculated by adding oral supplement consumption to spontaneous food intake, asking to record the number of bricks of supplements or parts therefore.

Patient monitoring

At the initial assessment body weight was measured to an accuracy of 0.5 Kg and body mass index computed as body weight/(height²). Bipolar body electrical bioimpedance was used to determine body composition⁸. An electric current of 0.8 mA and 50 kHz was produced by a calibrated signal generator (Biodynamics Model 310e, Seattle, WA, USA) and applied to the skin using adhesive electrodes placed on right-side limbs. Resistance and reactance were used to calculate total body water, fat and fat-free mass. Regional changes in body mass were estimated by measuring the circumferences and tricipital skinfold of the midarm. Radiotherapy treatment was recorded and the presence of mucositis, too. Ambulatory postoperative complications were recorded as none, general infections (respiratory tract infection and/or urinary tract infection) and local complications such as fistula and/or wound infection, assessed all complications with standard methods by the same investigator. Gastrointestinal problems related to enteral feeding were also recorded (diarrhea or vomiting).

Assays

Fasting blood samples were drawn for measurement of, albumin (3,5-4,5 gr/dl), prealbumin (18-28 mg/dl), transferrin (250-350 mg/dl), and lymphocytes (1.2-3.5.10³/uL) with an auto analyzer (Hitachi, ATM, Mannheim, Ger). CRP (c-reactive protein) was measured by immunoturbimetry (Roche Diagnostics GmbH,

Mannheim, Germany), analytical sensitivity 0.5 mg/dl. Samples were assayed in duplicate in one day by the same investigator to avoid inter-investigator variability.

Statistical analysis

The results were expressed as mean standard deviation. The distribution of variables was analyzed with Kolmogorov-Smirnov test. Quantitative variables with normal distribution were analyzed with two tailed paired or unpaired Student's t-test, as needed and analysis of variance (ANOVA). Non-parametric variables were analyzed with the Friedman and Wilcoxon tests. A p-value under 0.05 was considered statistically significant.

Results

Thirty nine patients were enrolled in the study. The mean age was 60.2±13.1 years (9 female/30 males). Epidemiological data of population are shown in table II. Duration of supplementation was 90.8±20 days.

Total calorie and protein consumption, based on both formula and dietary intake with 3 days food records, was (calories 2252±865 kcal/day) and (proteins: 100.1±26.4 g/day). As shown in table III, a significant increase of albumin, prealbumin and transferrin levels were observed. No differences were detected in weight and other anthropometric parameters (table IV).

Gastrointestinal tolerance (diarrhea and vomiting) was good, without cases during the protocol follow up. There were no dropouts due to intolerance. Ten patients (41.3%) received radiotherapy along the enhanced supplementation period and only 5 (20% of patients with radiotherapy) developed a clinical oral mucositis.

Discussion

Malnutrition and immunosuppression were two factors of head and neck cancer patients⁹⁻¹⁰. There is a

Table II

Patients characteristics

	Group N = 18
Age (years)	60.2±13.1
Men/women	29/10
Body weight (kg)	69.0±9.6
Disease Stage	
I	0
II	0
III	13
IV	26
Diagnosis of disease	
Oral cavity	10
Larynx	29

No statistical differences.

Table III

Visceral serum protein

Parameters	Basal	3 months
Albumin (g/dl)	3.1±0.6	4.12±0.7*
Prealbumin (mg/dl)	21.4±6.3	22.4±5.9*
Transferrin (mg/dl)	198.8±45.2	253.8±60.7*
Lymphocytes (10 ³ uL/mm ³)	1854.1±753	1654±881

* (p<0.05) with basal values.

Table IV

Evolution of anthropometric parameters

Parameters	Group	
	Baseline	3 months
BMI(kg/m ²)	24.5±9.1	24.6±10.2
Weight (kg)	69.0±9.6	70.4±10.6
Fat free mass(kg)	50.1±9.3	49.3±8.1
Fat mass(kg)	19.1±9.0	21.1±8.6
Tricipital skinfold(mm)	12.6±6.7	12.9±4.9
Circumference arm (cm)	27.3±3.4	27.1±4.1

No statistical differences between time 0 and at 3 months.

body of evidence suggesting that enteral feeding; supplemented with immunomodulatory agents including arginine and glutamine reduce postoperatively complications. The main result of our open study is a significant increase on serum protein levels after this supplementation with a low rate of oral mucositis episodes.

Our group has demonstrated in head and neck cancer patients with enteral arginine enhanced after surgery an improvement in weight and complications rate, during Hospital stance⁶. However, all these previous studies^{6,11,12} have been performed with income patients, with a short period of enteral nutrition. In our study, we analyze ambulatory patients during three months of oral supplementation, with a significant increase in seric protein levels and no changes in anthropometric parameters. Taking account, the low rate of adverse effects and the improvement in this biochemical parameters, this strategy of nutritional oral supplementation could be a way to treat this ambulatory patients.

Polymeric formulas are suitable for head and neck cancer patients, considering that the gastrointestinal tract distal to the oropharynx is usually normal and the digestion and absorption functions are intact. Various studies demonstrate that early use of enteral feedings during head and neck cancer treatment reduces weight loss, malnutrition, dehydration and the associated need for hospitalization or treatment interruption^{13,14}. However, immunoenhanced formulas could be used, too due to specific problems of these type of patients such as mucositis and coadjutants treatments.

Oral mucositis appeared in 80% of patients with head and neck cancer receiving radiotherapy¹⁵. Our patients had oral mucositis in a low rate (20% of the patients with radiotherapy). Although our design is not a randomized clinical trial, the incidence of oral mucositis is lower than previously reported in the literature. Glutamine, a non-essential amino acid widely distributed throughout the body, can behave as an essential amino acid in certain clinical settings. A number of studies have also examined the use of enteral glutamine or the treatment a prevention of mucositis. Although our daily dose of glutamine was lower (10 g per day or 0,15 g per kg and day), perhaps the glutamin administration in a viscous vehicle (such as Impact oral ® that will allow it to “stick” the mucosa could explain the low rate of mucositis in patients with radiotherapy.

In conclusion, at dose used, arginine and glutamine enhanced formula improved seric protein levels in ambulatory postoperative head and neck cancer patients with a low rate of oral mucositis in the subgroup with radiotherapy. Further randomized studies will be needed to confirm these preliminary results and to avoid potential bias.

References

1. Arriaga MA, Johnson JT, Kanel KT, Myers EN. Medical complications in total laryngectomy: incidence and risk factors. *Ann Otol Rhinol Laryngol* 1990; 99: 611-615.
2. Van Bokhorst-de van der Schueren MAE, von Blomberg-vander Flier BME, Riezebos RK. Differences in immune status between well-nourished and malnourished head and neck cancer patients. *Clin Nutr* 1998; 17: 107-111.
3. Meydani S. Effects of (N-3) polyunsaturated fatty acids on cytokine production and their biological function. *Nutrition* 1996; 12: S8-12.
4. Wigmore SJ, Barber MD, Ross JA. Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer. *Nutr Cancer* 2000; 36: 177-184.
5. de Luis Da, Izaola O, Aller R, Cuellar L, Terroba MC, Martin T. A randomized clinical trial with two omega 3 fatty acid enhanced oral supplements in head and neck cancer ambulatory patients. *Eur Revi Med Pharmacol Sci* 2008; 12: 177-181.
6. de Luis DA, Aller R, Izaola O, Cuellar L, Terroba MC. Post-surgery enteral nutrition in head and neck cancer patients. *Eur J of Clin Nutr* 2002; 56: 1126-1129.
7. Cerchiotti LC, Navigante AH, Lutteral MA, Castro MA, Kirchuk R, Bonomi M, Cabalar ME, Roth B, Negretti G, Sheinker B, Uchima P. Double-blinded, placebo-controlled trial on intravenous L-alanyl-L-glutamine in the incidence of oral mucositis following chemoradiotherapy in patients with head-and-neck cancer. *Int J Radiat Oncol Biol Phys* 2006 Aug 1; 65(5): 1330-7
8. Pichard C, Slosman D, Hirschel B and Kyle U. Bioimpedance analysis: an improved method for nutritional follow up. *Clin Res* 1993; 41: 53^a.
9. Riboli E, Kaaks R, Esteve J. Nutrition and laryngeal cancer. *Cancer causes and Control* 1996; 7: 147-156.
10. Bassett MR, Dobie RA. Patterns of nutritional deficiency in head and neck cancer. *Otol Head Neck Surg* 1983; 91: 119-125.
11. Gianoti L., Braga M, Fortis C, Soldini L, Vignali A, Clombo S, Radaelli G, Di Carlo V. A prospective, randomized clinical trial on perioperative feeding with an arginine, omega-3 fatty acid, and RNA-enriched enteral diet. Effect on host response and nutritional status. *J of Parenteral and Enteral nutrition* 1999; 23: 314-320.
12. Coghlin-Dickson TM, Wong RM, Offrin RS, Shizuru JA, Johnston LJ, Hu WW, Blume KG. Efectc of oral glutamine supplementation during bone marrow transplantation. *JPEN* 2000; 24: 61-66.
13. Goncalves Dias MC, de Fatima Nunes M, Nadalin W, Waitzberg DL. Nutritionl intervention improves the cloric and proteic ingestion of head and neck cancer patients under radiotherapy. *Nutr Hosp* 2005; 20: 320-325.
14. Ravasco P, Monteiro.Grillo I, Vidal PM, Camilo ME. Impact of nutrition on outcome: a prospective randomized controlled trial in patients with head and neck cancer undergoing radiotherapy. *Head and Neck* 2005; 10: 659-668
15. Trotti A, Bellm AL, Epstein BJ, Frame D, Fuhs JH, Gwede KC, Komaroff E, Nalysnyk L. Mucositis incidence, severity and associated outcome in patients with head and neck cancer receiving radiotherapy with or without chemotherapy a systematic literature review. *Radiotherapy and oncology* 2003; 66: 253-262.
16. Wischmeyer PE. Clinical applications of L glutamine: past, present and future. *Nutrition and Clinical practice* 2003; 18: 377-385.